Table II.
HA-1–specific Lysis of Nonhematopoietic Tumor Cell Lines
| Percent-specific lysis byallo HLA-A2 CTLs
|
Percent-specific lysis byHLA-A2/HA-1 CTLs
|
|||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
1E2IFNγ/TNFα
|
5W38IFNγ/TNFα
|
3HA15IFNγ/TNFα
|
|||
| Tumor type | Target cell designation | E/T ratio | no | yes | no | yes | no | yes |
| A2 HA-1H | ||||||||
| Breast cancer | MDA-MB231 | 2:1 | 10 | 13 | 8 | 15 | 8 | 13 |
| 10:1 | 50 | 64 | 31 | 47 | 25 | 39 | ||
| Melanoma | MEL 93.04 | 2:1 | 10 | 14 | 1 | 13 | −2 | 10 |
| 10:1 | 54 | 64 | 12 | 37 | 17 | 40 | ||
| Melanoma | 453 AO | 2:1 | 7 | 24 | 1 | 10 | 1 | 18 |
| 10:1 | 25 | 43 | 5 | 21 | 2 | 22 | ||
| 20:1 | 35 | 45 | 7 | 24 | 7 | 21 | ||
| Lung carcinoma | GLC 36 | 1:1 | 33 | 35 | 6 | 12 | 0 | 8 |
| 10:1 | 59 | 80 | 8 | 25 | 17 | 25 | ||
| Colon carcinoma | CaCo-2 | 1.6:1 | 20 | 22 | 1 | 2 | 6 | 7 |
| 16:1 | 29 | 49 | 4 | 4 | 11 | 17 | ||
| A2 HA-1R | ||||||||
| Breast cancer | 734B | 2:1 | 29 | 41 | 3 | 1 | 4 | 0 |
| 10:1 | 32 | 67 | 5 | 1 | 0 | 0 | ||
| Melanoma | MNT | 1:1 | 33 | 51 | 0 | 0 | 1 | 1 |
| 10:1 | 62 | 84 | 3 | 3 | 0 | 0 | ||
| Melanoma | BT | 1:1 | 33 | 36 | 0 | 0 | 0 | 4 |
| 10:1 | 76 | 79 | 0 | 0 | 0 | 9 | ||
| A2-ve | ||||||||
| Breast cancer | ZR75-1 | 1:1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 10:1 | 0 | 2 | 1 | 6 | 0 | 0 | ||
| Controls | ||||||||
| EBV-LCLs | A2 HA-1H | 1:1 | 60 | ND | 35 | ND | 24 | ND |
| 10:1 | 87 | ND | 43 | ND | 43 | ND | ||
| A2 HA-1H | 1:1 | 69 | ND | 51 | ND | 32 | ND | |
| 10:1 | 83 | ND | 41 | ND | 68 | ND | ||
| A2 HA-1R | 1:1 | 54 | ND | 6 | ND | 4 | ND | |
| 10:1 | 81 | ND | 3 | ND | 0 | ND | ||
| A2 HA-1R | 1:1 | 55 | ND | 0 | ND | 1 | ND | |
| 10:1 | 83 | ND | 1 | ND | 0 | ND | ||